France Healthcare Market Report 2026: HAS Market Access, Assurance Maladie, and Commercial Intelligence

The French healthcare market is estimated at EUR 255–270 billion in 2026, representing approximately 12.1% of GDP. France operates a universal healthcare system (Assurance Maladie, colloquially called "la Sécu") funded through payroll contributions and general taxation. Approximately 77% of healthcare costs are covered by the Assurance Maladie (CNAM), with complementary insurance (mutuelles and assurances complémentaires) covering an additional 13% on average, leaving approximately 10% as out-of-pocket expenditure. France has approximately 3,000 hospitals (public and private), 74,000 community pharmacies, and 220,000+ physicians.

The French pharmaceutical market is estimated at EUR 32–35 billion in 2026, making it the second-largest pharmaceutical market in the EU after Germany. The Assurance Maladie reimburses approved medicines at rates ranging from 15% to 100% depending on therapeutic value. HAS (Haute Autorité de Santé) Transparency Commission assesses all new medicines for SMR (Service Médical Rendu, medical benefit) and ASMR (Amélioration du Service Médical Rendu, improvement of medical benefit), with ASMR ratings I–V (I = major improvement, V = no improvement demonstrated). Price negotiations for reimbursed products are conducted by CEPS (Comité Économique des Produits de Santé).

The French HAS (Haute Autorité de Santé) Transparency Commission conducts benefit assessment for all new medicines seeking reimbursement. The two-stage assessment assigns: (1) SMR (medical benefit level) — the absolute benefit rating (major/important/moderate/low/insufficient) that determines reimbursement rate; and (2) ASMR (improvement of medical benefit) — the comparative added benefit against the comparator (ratings I–V). Products with ASMR I–III typically receive a price premium versus existing treatments. Products with ASMR IV or V are generally priced at or below the comparator. Early access (Autorisation d'Accès Précoce, AAP — replacing the former ATU system) enables HAS-assessed pre-approval access for promising therapies. Price negotiations with CEPS follow HAS assessment.

The five largest therapy areas in the French pharmaceutical market by Assurance Maladie reimbursement spend are: oncology (fastest-growing, driven by immunotherapy, targeted therapy, and cancer hospital budgets); cardiovascular (high volume: statins, anticoagulants, antihypertensives); immunology and biologics (TNF inhibitors, IL-17/23 inhibitors, JAK inhibitors, with growing biosimilar penetration); diabetes (GLP-1 agonists growing rapidly, insulin at high volume); and respiratory (COPD biologics, dupilumab for severe asthma, ICS/LABA combinations). The AAP early access pathway is particularly active in oncology and rare diseases.

The French medical devices market is estimated at EUR 14–16 billion in 2026. ANSM (Agence nationale de sécurité du médicament et des produits de santé) is the national competent authority for market surveillance under EU MDR. Medical devices seeking reimbursement through the Assurance Maladie must be listed on the LPP (Liste des Produits et Prestations). HAS CNEDIMTS (Commission nationale d'évaluation des dispositifs médicaux et des technologies de santé) assesses the ASA (added value) of new devices for LPP listing. The Forfait Innovation pathway enables early conditional reimbursement for genuinely innovative devices.

BioNixus supports French and wider European pharmaceutical and medical device companies in expanding into GCC and MENA markets. From our London office, we provide SFDA (Saudi Arabia), MOHAP (UAE), and GCC-wide regulatory pathway intelligence; NUPCO tender intelligence and hospital formulary data; physician panel surveys across all major therapeutic areas in Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, and Egypt; and comparative EU vs. GCC market intelligence for global commercial and market access strategy. BioNixus bridges European evidence standards with GCC commercial realities.